高脂血症是动脉粥样硬化的危险因素，与冠心病、中风及股动脉狭窄等病症息息相关，严重威胁人类健康。他汀类药物因确切的疗效，已成为大多数临床医生的首选。但大剂量服用他汀类药物会产生肌毒和肝转氨酶升高，并不适用于所有的心血管类疾病。此外贝特类和烟酸类药物会产生胃肠道不适和肝肾损伤。因此寻找疗效显著、安全可靠的调血脂药一直是医药工作者长期研究的课题。综述基于Pubmed上关于人高脂血症（胆固醇、三酰甘油、LDL-C、HDL-L）主要治疗药物的相关研究，对近年来调血脂药物研究进展进行综述

Hyperlipidemia, the risk factor of atherosclerosis, closely related to the coronary heart disease, stroke, and the artery stenosis disease, is seriously threatening human health. Statins for the exact curative effects, has become the first choice to the most of the doctors in clinic. However, a large dosage of statins would cause muscle poison and associated increase in the hepatic transaminases, which is not suitable for all the cardiovascular diseases. In addition, Fibrates and niacin sequestrants would causee discomfort of gastrointestinal tract and damage of liver and kidney. Therefore, looking for the safe and reliable lipid-lowering drug with remarkable curative effect has been a project with long-term research for medicinal workers. This article reviewed the studies on new hypolipidemic drugs in recent years, which could mainly treat the hyperlipidemia (cholesterol, triglyceride, LDL-C, and HDL-L) based on the papers in the Pubmed.